ALKERMES | ALKS - Attività Correnti





Attività Correnti Cambiamento Data
AbbVie USD 37.48B 3.81B 2026-09
Acadia Pharmaceuticals USD 1.27B 43.88M 2026-09
ALKERMES USD 1.58B 57.83M 2026-09
Amgen USD 34.36B 598M 2026-09
Biogen USD 7.58B 278.7M 2026-09
BioMarin Pharmaceutical USD 3.92B 50.99M 2026-09
Bristol-Myers Squibb USD 29.77B 1.19B 2026-09
Coherus Biosciences USD 133.79M 72.25M 2026-06
Eli Lilly USD 65.26B 591M 2026-09
Gilead Sciences USD 16.55B 4.02B 2026-09
Heron Therapeutics USD 209.11M 20.73M 2026-09
Ionis Pharmaceuticals USD 2.36B 129.77M 2026-09
J&J USD 56.35B 3.42B 2026-09
Malin Corporation EUR 62.6M 26.7M 2024-12
Merck USD 38.94B 2.26B 2026-09
Minerva Neurosciences USD 83.1M 70.08M 2025-12
Nektar Therapeutics USD 589.04M 322.77M 2026-03
Neurocrine Biosciences USD 2.01B 370.7M 2026-09
Otsuka Holdings JPY 1.6T 29.58B 2026-09
Ovoca Bio EUR 2.07M 510K 2025-12
Pfizer USD 45.01B 3.65B 2026-09
Regeneron Pharmaceuticals USD 20.8B 2.35B 2026-09
Vertex Pharmaceuticals USD 11.69B 857.4M 2026-09